Leal, T., Halmos, B., Florez, N., Iams, W. T., Johnson, M. L., Goldberg, S. B., Le, X., Puri, S., Nguyen, D., Raez, L. E., Riess, J. W., Sabari, J. K., Bjork, D., Stigger, N., Tang, R., Xia, K., Cifuentes, P., Shanoon, F., Leipoldt, I., Konduri, K. (2026). COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in
                    <i>EGFR</i>
                    -mutated advanced NSCLC: Interim results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8614